Recruiting

GLP-1 & SDC

Sponsor:

Purdue University

Code:

NCT07572513

Conditions

Blood Glucose

GLP-1

Satiety

Second Meal Intake

Healthy Participant Study

Eligibility Criteria

Sex: All

Age: 18 - 45

Healthy Volunteers: Accepted

Interventions

Maltodextrin (Placebo)

Raw Corn Starch

Study Details

Brief summary:

The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss.

Researchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 60, 120, 180 minutes and after a second meal.

There will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will:

  • Consume a randomized test beverage (SDC or maltodextrin)
  • Receive a blood draw at 7 timepoints over 3 hrs
  • Take a satiety questionnaire 5 times over 3 hrs
  • Consume a standardized lunch 3 hrs after the test beverage consumption

Conditions

Blood Glucose

GLP-1

Satiety

Second Meal Intake

Healthy Participant Study

Study ID

NCT07572513

Start date

May 1, 2026

Status verified date

May, 2026

Completion date

Nov 25, 2026

Anticipated

Primary completion date

Jul 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 45

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Healthy population
2. BMI between 18.5 and 24.9 kg/m2
3. Adults 18 - 45 years old
4. Men or women
5. Able to read/speak English
6. Fasting blood glucose levels ≤100 mg/dL
7. HbA1c ≤ 5.7%

Exclusion Criteria:

1. Participants with 18 > Years of Age > 45 will be excluded.
2. Subjects with 18.5 kg/m² > BMI > 24.9 kg/m² will be excluded.
3. Diabetic individuals will be excluded.
4. Individuals with history of gastrointestinal disease will be excluded from the study.
5. Pregnant or nursing women will also be excluded.
6. Individuals taking GLP-1 medications, or on weight-loss diets or restrictive eating patterns.
7. Individuals suffering from dairy or gluten intolerance or allergies will be excluded.

Study Design

Enrollment

19 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

placebo comparator: Maltodextrin

Maltodextrin increases GLP-1 from 0-60 minutes but doesn't have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume a treatment that is either entirely maltodextrin or partially maltodextrin during each of the 4 study visits.

experimental: Low-Dose SDC

20 g of raw corn starch (SDC) + 55g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the low-dose once during one of the study visits.

experimental: Medium-Dose SDC

40 g of raw corn starch (SDC) + 35g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the medium-dose once during one of the study visits.

experimental: High-Dose SDC

60 g of raw corn starch (SDC) + 15g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the high-dose once during one of the study visits.

Interventions

Maltodextrin (Placebo)

75 g of maltodextrin diluted in 200 mL of water, taken once at a study visit

Raw Corn Starch

Quantity of raw corn starch will vary between low, medium, and high-dose treatment arms (20, 40, 60 g respectively). Each treatment will total 75 g using maltodextrin to account for mass difference (55, 35, 15 g respectively).

Primary outcome measure

  • Total GLP-1 Secretion [ Time Frame: From baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of treatment for each participant over the course of the 4 arms. ]

Central Contacts and Locations

Central contacts

Bruce R Hamaker, Ph.D.

765-494-5668hamakerb@purdue.edu

Erica de Jong, B.s.

7654963802dejonge@purdue.edu

Locations

Clinical Research Center at Purdue University

Recruiting

West Lafayette, Indiana, United States, 47907

Contacts

Cheryl Armstrong, Ph.D.

765-496-6275armstroc@purdue.edu

More Information

Sponsor

Purdue University

Last update posted

May 7, 2026

Last verified

May, 2026

Keywords

  • GLP-1
  • Slowly-Digestible Starch
  • Ileal-Digesting Starch
  • Dietary Starch
  • Satiety
  • Starch
  • raw corn starch
  • Blood Glucose

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Purdue University on 2026-05-07.